Dear FTD Community,

We are writing today with an important and encouraging update on ASPIRE-FTD, our Phase 1/2 clinical trial evaluating AVB-101 for people living with frontotemporal dementia (FTD) caused by GRN gene mutations (FTD-GRN).

The trial is growing: We are pleased to announce that the ASPIRE-FTD trial is now opening a fourth cohort, offering up to six additional patients the opportunity to be dosed. This is a meaningful milestone in our dose-escalation trial and reflects the continued momentum of this research. The data gathered to date is promising, and we are proud of the progress our team and clinical partners have made together.

The reach is expanding: ASPIRE-FTD is now active across multiple sites in Belgium, Canada, Italy, the Netherlands, Poland, Spain, Sweden, the United Kingdom, and the United States. This expansion reinforces our deep commitment to enabling access and participation for families navigating this devastating diagnosis, wherever they may be.

"We know that FTD-GRN is a rapidly progressing disease with a narrow window of opportunity for families considering clinical trial participation. We also anticipate that the greatest potential benefit may be for those in the earliest stages of disease after symptoms become apparent— underpinning the importance of awareness and action within that window when considering participation in a clinical trial like ours. We encourage anyone who may be interested to speak with their neurologist to determine if they are eligible,” said David Cooper, MD, Chief Medical Officer, AviadoBio.

Thank you to the patients and families who have participated: The courage and trust it takes to be part of early-stage research is not something we take lightly. Your contributions are advancing important science and bringing real hope to the broader FTD community. We are honored to be on this journey with you.

We look forward to sharing further updates as the trial progresses, and we remain deeply committed to strengthening our collective understanding of FTD-GRN and to finding the treatments this community so urgently needs and deserves.

For more information about ASPIRE-FTD and to explore eligibility, please visit www.aspire-ftd.com or the full study listing at www.clinicaltrials.gov/study/NCT06064890.

With gratitude and determination,
The AviadoBio Team